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A cDNA clone of the bovine immunodeficiency-likevirus (BW) trans-activator gene (tat) was identified and
characterized. The tat cDNA clone was generated by splicing, and on the basis of sequence analysis, the Tat
protein was found to be encoded entirely by the first exon. It is 103 amino acids in size and shares sequence
homology with the human immunodeficiency virus (HW) Tat. The BIV tat clone can trans activate the BIV
promoter effectively, as measured by the expression of the bacterial chloramphenicol acetyltransferase gene,
when transfected into bovine cells. Besides activating the BIV promoter, the BIV Tat can also trans activate the
HIV promoter effectively. It is possible that BIV Tat and HIV Tat employ similar mechanisms in trans
activation of the viral long terminal repeat-directed gene expression.
Bovine immunodeficiency-like virus (BIV) is a recently
characterized bovine lentivirus which causes lymphadenopathy, lymphocytosis, and central nervous system disorders
in infected cattle (3, 22). The virus has been cloned, and the
nucleotide sequence of the BIV genome has been determined (4, 10). The genome is approximately 9.0 kb in size
and contains the structural genes gag, pol, and env, as well
as other open reading frames analogous to the vif, tat, and
rev genes of human immunodeficiency virus (HIV) (6,7,10).
The HIV tat gene is an important regulatory gene (6, 8).
Several studies have shown that HIV Tat increases the
steady-state level of HIV mRNA in part by increasing the
rate of transcription initiation (14, 15) and the efficiency of
transcription elongation (12). It has been demonstrated recently that BIV-infected cells also express a trans-acting
protein, similar to the HIV Tat (18). However, the tat gene
of BIV has not been identified, and its trans-activation
function has not been demonstrated. Analysis of the BIV
transcriptional pattern by Northern (RNA) blot indicated
that multiple transcripts were expressed, and several subgenomic viral RNAs that can potentially encode the BIV Rev
and Tat proteins were detected (17). In order to specifically
identify and characterize the BIV tat gene, we used polymerase chain reaction to amplify viral mRNAs that can
potentially encode the Tat protein.
Cloning of BIV tat by polymerase chain reaction. On the
basis of the BIV genomic sequence analyses (lo), it was
predicted that BIV tat is encoded by two exons (Fig. 1A).
The first is encoded by an exon 5' of the envelope gene from
nucleotides (nt) 5228 to 5536, and the second is encoded by
an exon located within the envelope gene from nt 7657 to
7782. In order to clone both tat exons, three different
primers were used to amplify BIV-infected embryonic bovine lung (EBL) cell mRNA. The first primer, PT1, should
prime 5' to the first predicted tat exon, and the second
primer, PT2, should prime 3' of the predicted second exon
(Fig. 1B). The third primer, PT3, was also used in place of
PT2 to prime at the poly(A) tail located at the 3' end of tat
mRNA. Several clones were generated by either the first
(PT1 and PT2) or the second (PT1 and PT3) set of primers.
One clone generated from the first primer set (TATC-1) and
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one clone from the second primer set (TATC-2) were further
mapped and characterized. They were found to be very
similar. Both c a n y exons 1 and 2 of the putative tat gene
(Fig. 1C). The TATC-1 insert is smaller and terminates at the
end of the second tat exon at nt 7787, where the PT2 primer
binds. The TATC-2 clone is larger, and its second exon
extends to the 3' end of the BIV genome, all the way to the
polyadenylation site at nt 8485. The nucleotide sequence of
TATC-1, its deduced amino acid sequence, and a comparison with a previously published BIV genomic sequence (10)
are shown in Fig. 2. The sequence of our cDNA clone
TATC-1 is very similar to the published genomic clone
sequence: there are only three nucleotide differences between the two sequences, and two of these changes led to
amino acid substitutions. Our cDNA sequence also indicates
that the splice junction between tat exons 1and 2 is different
from the one predicted earlier (10). Our sequence indicates
that the splice donor and acceptor sites for tat exon 2 are
located at nt 5541 and 7638, respectively, whereas the
previously predicted locations were at nt 5536 and 7657 (Fig.
1 and 2). Interestingly, the splice junction for tat is identical
to that previously mapped for the BIV rev gene (17). In
addition, our cDNA clone has three in-frame stop codons:
one can be found before the splice junction, and the other
two are in the second exon immediately after the splice
junction. This suggests that the second exon may not encode
any Tat protein sequence and that the 103-amino-acid (103aa) Tat protein is encoded entirely within the first exon.
The translated TATC-1 sequence displays several common features that are found in other lentiviral Tat proteins
(5). There is a cysteine-rich domain (aa 38 to 46) containing
a cluster of five cysteines. Mutations of these analogous
cysteine residues in HIV can abolish Tat function completely
(13). There is also a core region of BIV Tat, HCQLCF
LQ-KNBL NYY (aa 49 to 64), which bears striking homology
to the HIV core region, HCQVCFTI'KALGISYG (aa 33 to 48).
Alignment of the HIV-1 and BIV Tat sequences indeed shows
a 54% amino acid homology within their cysteine-rich and core
regions; both regions are essential for HIV-1 Tat protein to
function in tram activation (5). In the BIV Tat protein, there
also exists a basic domain, RGKGRRIRR (aa 73 to 81), which
bears some homology to the domain (RKKRRQRRR) found in
HIV-1 (19). This domain was predicted to be the nuclear
localization motif for HIV. Further experiments are required to
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FIG. 1. (A) Schematic representation of organization of the BIV
genome. The predicted B N tat exon 1is indicated by the solid box,
and exon 2 is indicated by the slashed box. Numbers indicate the
predicted nucleotide positions of the tat exons (10). (B) Locations of
primers used for cloning tat cDNA and the BIV LTR. The primers
(nt 7953 to
are as follows: PL1, 5'-CGCCACGCTCCTATTlTA-3'
7970), which is located in the 5' end of the U3 region of the LTR;
PL2, 5'-CCGAGCCAGTGCCTCTC-3' (nt 8435 to 8419, an antisense primer), which is located in the R region of the LTR; PT1,
5'-CAlTCATAGAlTGTGGCA-3' (nt 5208 to 5225), which is located before the predicted tat exon 1; PT2, 5'-GlTCAACCAAT
TCTCGTAGA-3' (nt 7787 to 7768, an antisense primer), which
spans the predicted stop codon of tat exon 2; and PT3, 5'-lTGTC
, '3G
-A
which is an oligo(dT) primer w n taining a SalI recognition site at the 5' end. PCR, polymerase chain
reaction. (C) Schematic representation of the two tat cDNA clones
obtained with primers PT1 and PT2 (TATC-1) and with primers PT1
and PT3 (TATC-2). Numbers indicate the nucleotide positions and
the location of the splice junction between tat exons 1 and 2. R, R
region.

demonstrate the functions of these domains in the BIV Tat
protein.
The &af cDNA clone can trans activate the BlV promoter. To
test whether our tat cDNA clone can trans activate BIV long
terminal repeat (LTR) expression, a BIV-CAT construct
which contains the chloramphenicol acetyltransferase (CAT)
gene under the control of the BIV LTR was made. Our tat
cDNA clone TATC-2 was also cloned into a plasmid under
the control of the simian virus 40 promoter to generate the
tat expression vector pBTATC. This clone was then cotransfected into EBL cells along with the BIV-CAT plasmid to
check for trans activation of CAT expression. In the presence of pBTATC, BIV-CAT was activated and resulted in a
20-fold increase in CAT activity (Table 1). Since the putative
Tat protein is encoded entirely by the first exon, our results
suggest that exon 1 alone is sufficient for trans activation of
the BIV LTR. To further confirm that a functional BIV Tat
protein can be entirely encoded by only one exon, a second
BIV-tat clone was generated from the genomic BIV clone
(1). This plasmid, pBTATG, was constructed by inserting
the BIV proviral DNA fragment containing an intact proviral
5' LTR and the predicted tat exon 1 into a pUC18 vector.
This genomic clone thus lacks the second tat exon and the 3'
end of the BIV genome. When pBTATG was cotransfected
into EBL cells along with BIV-CAT, trans activation of the
BIV LTR-directed CAT expression was observed. There
was a 25-fold increase of CAT activity in the presence of
pBTATG (Table 1). Interestingly, the genomic pBTATG
clone consistently yields slightly higher levels of trans-acting
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FIG. 2. Nucleotide sequence and translated amino acid sequence
of BIV tat cDNA clone TATC-1. Nucleotide numbers are given at
the top, and the amino acid numbers are given on the side. The
TATC-1 sequence (top sequence) and the published BIV tat genomic sequence (10) (bottom sequence) are shown. The dashed line
represents sequence identity between TATC-1 and the published
genomic sequence, and the differences in the sequences are indicated. The arrow between nt 314 and 315 represents the splice
junction between tat exons 1 and 2; < > represents the predicted
splice donor and acceptor sites (10). Termination wdons are also
indicated (boldface).

activity than our tat cDNA clone, pBTATC. It is possible
that pBTATG, which uses the BIV LTR as a promoter, is
more effective in expressing tat mRNA, and the Tat protein
produced may in turn provide positive feedback to further
trans activate the BIV LTR.
BIV Tat is similar to HlV Tat and can trans activate the HIV
LTR. Since the BIV Tat protein sequence shares some
homology with the HIV-1 Tat core and cysteine-rich regions
(19), it would be of interest to test whether BIV Tat could
trans activate the HIV LTR and vice versa. EBL cells were
either transfected with HIV-CAT (11) alone or cotransfected
with the BIV tat cDNA clone pBTATC or genomic clone
pBTATG. The results in Table 1show that the HIV LTR can
indeed be trans activated by BIV Tat and that the presence
of pBTATC or pBTATG elevated HIV LTR-directed CAT
gene expression by approximately 8- and 18-fold, respectively. Even though this level of trans activation is significant, it is still lower than the previously observed 50- to
100-fold activation of the HIV LTR by its homologous HIV
tat gene product. In bovine cells, the lower level of activation of the HIV LTR by BIV Tat cannot be due to the
absence of appropriate cellular factors, since the HIV LTR
can be activated by HIV Tat by approximately 101-fold in
these cells (Table 1). Thus, the lower level of trans activation
of the HIV LTR by BIV Tat may simply reflect structural
differences between HIV and BIV Tat proteins. The trans
activation of HIV-CAT by BIV Tat is specific; other viral

NOTES
TABLE 1. trans activation of CAT promoter constructs by
different tat plasmids0
Construct and
plasmid

CAT enzyme activity
(cpm.lO6cells)b

Fold
activation

BIV-CAT
None
pBTATC
pBTATG
HIV TAT
HIV-CAT
None
pBTATC
pBTATG
HIV TAT
ABIV-CAT
None
pBTATC
pBTATG
pSV,-CAT
None
pBTATC
HTLV-I-CAT
None
pBTATC
a EBL cells were transfected with 2 pg of CAT plasmid and 10 pg of tat
plasmid by the standard calcium phosphate precipitation procedures (2).
Transfected cells were harvested at 48 h for CAT analyses. AU samples were
corrected for protein concentration variations before they were assayed.
Procedures for CAT assays with ['H]acetyl coenzyme A were described
previously (16).
The amount of CAT enzyme activity per lo6 transfected cells was
measured over a 5-h period, and the values were calculated by taking the slope
of the linear portion of the curve and expressed as counts per minute
incorporated over a 1-h period.

promoters, such as the human T-cell leukemia virus type I
promoter construct (HTLV-I-CAT) or the simian virus 40
viral promoter construct (pSV,-CAT), cannot be trans activated by BIV Tat (Table 1). In addition, the BIV LTR can
also be trans activated when cotransfected into EBL cells
with the heterologous HIV tat expression plasmid (Table 1)
(11). However, the activation of the BIV LTR by HIV-1 Tat
is only about threefold and is much lower than the observed
20- to 25-fold activation by BIV Tat. Nevertheless, this
suggests that trans activation by the BIV Tat protein may
involve mechanisms similar to those of HIV Tat.
Z'hm activation of a deletion BIV LTR construct by BIV
Tat. The trans-activation target of HIV Tat has been well
characterized and is located downstream of the transcription
initiation site (9, 20). Similarly, the Tat responding element
for equine infectious anemia virus is also located within the
LTR (21). Since BIV and HIV Tat proteins may use similar
mechanisms in activation of their respective LTRs, it was of
interest to determine whether the target site of BIV Tat is
also located within the LTR. In order to test for the presence
of the BIV Tat responding element, a BIV LTR deletion
clone was tested. This clone, ABIV-CAT, was generated by
using polymerase chain reaction primers to specifically amplify the BIV LTR from the U3 region, up to position +64 in
the R region, with respect to the mRNA start site. The
amplified, deleted LTR was then cloned in front of the CAT
gene to study LTR-directed CAT expression. When ABIVCAT was cotransfected into EBL cells along with the
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pBTATC or pBTATG plasmid, even though activations of
ABIV-CAT were still observed, the levels of trans activation
were much lower (Table 1). Levels of activation of ABIVCAT by pBTATC and pBTATG were about six- and threefold lower than those of intact BIV-CAT, respectively. Our
results suggest that the deletion in ABIV-CAT has removed
part of the cis-acting target element which may be involved
in the Tat-directed trans activation.
Our study provides further evidence to support the idea
that there are similarities between BIV and other lentiviruses, such as HIV. Not only are there similarities in
genomic organization, nucleotide sequence (lo), and antigenicities (I), but the BIV Tat is also very similar to that of
HIV, as we have now demonstrated. These proteins appear
to function through similar mechanisms. Further elucidation
of the mechanism of Tat-mediated stimulation of BIV viral
gene expression will require detailed mutagenesis studies of
the functional domains of the BIV Tat protein and its
cis-acting trans-activation target element, as well as studies
to identify other cellular proteins that may be involved.
Nucleotide sequence accession number. The GenBank nucleotide sequence accession number for the BIV tat gene is
M90681.
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thank S. Mason for preparation of the manuscript.
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